Personnel de l'université
Vincent SAUZEAU
Research director (DR2 Inserm) Co-leader team III : Vascular and lung diseasesCoordonnées
Inserm UMR 1087 l'institut du thorax IRT - UN 8 quai Moncousu BP 70721 44007 Nantes Cedex 1
- Bureau
- 241b
- Tél
- 0228080174 (n° interne : 320174)
- Vincent.Sauzeau@univ-nantes.fr
- Site internet
- https://umr1087.univ-nantes.fr/research/research-teams/team-iii-members-1
Activités / CV
V. Sauzeau is an expert in the analysis of intracellular signaling in vascular and airways smooth muscle cells, recognized for its expertise in the role of Rho proteins in physiology and physiopathology.
After obtaining his PhD from the University of Nantes in 2003, he trained as a postdoctoral fellow at the Cancer Research Center in Spain (2004-2009). During this training, he received the Young Investigator and the Spanish biomedical research awards. Recruited by Inserm in 2009, he joined the laboratory of l'institut du thorax. His research is focused on Rho protein signaling and the identification of new therapeutic targets in vascular and pulmonary diseases. His research is funded by national grants and by the technology transfer office Ouest Valorisation.
He has authored or co-authored more than 40 articles in peer-reviewed journals and 6 patents. His achievement has been recognized by pharmaceutical companies: AstraZeneca (Target Innovation Program-2015) and Sanofi (Sanofi Innovation Award Europe-2020).
After obtaining his PhD from the University of Nantes in 2003, he trained as a postdoctoral fellow at the Cancer Research Center in Spain (2004-2009). During this training, he received the Young Investigator and the Spanish biomedical research awards. Recruited by Inserm in 2009, he joined the laboratory of l'institut du thorax. His research is focused on Rho protein signaling and the identification of new therapeutic targets in vascular and pulmonary diseases. His research is funded by national grants and by the technology transfer office Ouest Valorisation.
He has authored or co-authored more than 40 articles in peer-reviewed journals and 6 patents. His achievement has been recognized by pharmaceutical companies: AstraZeneca (Target Innovation Program-2015) and Sanofi (Sanofi Innovation Award Europe-2020).
Mis à jour le 24 février 2025.